Rotigotine Effect on All-day Functioning and Quality of Life in Subjects With Moderate to Severe Restless Legs Syndrome (RLS)
Public ClinicalTrials.gov record NCT01569464. Field values are reproduced from the official study page; the official ClinicalTrials.gov record remains the source of truth for eligibility, enrollment, and contact information.
Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.
Official title
A Phase 3B, Double-Blind, Randomized, Placebo-Controlled Study of Rotigotine and Its Effect on All-Day Functioning and Quality of Life in Subjects With Moderate to Severe Idiopathic Restless Legs Syndrome
Study identification
- NCT ID
- NCT01569464
- Recruitment status
- Completed
- Study type
- Interventional
- Phase
- Phase 3
- Lead sponsor
- UCB Pharma
- Industry
- Enrollment
- 150 participants
Conditions and interventions
Conditions
Interventions
- Rotigotine Drug
- Placebo Other
Drug · Other
Eligibility (public fields only)
- Age range
- 18 Years to 75 Years
- Sex
- All
- Healthy volunteers
- Healthy volunteers not accepted
This page does not interpret eligibility. Detailed inclusion and exclusion criteria are on the official ClinicalTrials.gov record.
Study timeline
- Start date
- Feb 29, 2012
- Primary completion
- Mar 31, 2013
- Completion
- Mar 31, 2013
- Last update posted
- Aug 25, 2014
2012 – 2013
United States locations
- U.S. sites
- 18
- U.S. states
- 14
- U.S. cities
- 18
| Facility | City | State | ZIP | Site status |
|---|---|---|---|---|
| 006 | Birmingham | Alabama | — | — |
| 013 | Jasper | Alabama | — | — |
| 021 | Gilbert | Arizona | — | — |
| 014 | Little Rock | Arkansas | — | — |
| 010 | Oceanside | California | — | — |
| 004 | Orange | California | — | — |
| 002 | Tampa | Florida | — | — |
| 012 | Macon | Georgia | — | — |
| 008 | Destrehan | Louisiana | — | — |
| 017 | Brighton | Massachusetts | — | — |
| 016 | Brockton | Massachusetts | — | — |
| 019 | Kalamazoo | Michigan | — | — |
| 015 | St Louis | Missouri | — | — |
| 007 | West Seneca | New York | — | — |
| 018 | Cincinnati | Ohio | — | — |
| 009 | West Chester | Pennsylvania | — | — |
| 003 | Austin | Texas | — | — |
| 005 | San Antonio | Texas | — | — |
Site contact phone numbers, emails, and investigator names are intentionally not displayed here. Open the official ClinicalTrials.gov record for site contact information.
About this trial record page
- What this page shows
- Public field values for ClinicalTrials.gov record NCT01569464, including study identification, conditions, interventions, eligibility (age, sex, healthy volunteer), timeline, and U.S. site list.
- What this page does not do
- No medical advice, eligibility judgments, treatment recommendations, study quality scoring, or AI-generated medical summaries. No site contact phone numbers, emails, or investigator names.
- Where the data comes from
- Sourced from the official ClinicalTrials.gov public API. The official record is the source of truth.
- Last refresh
- Last update posted Aug 25, 2014 · Synced Jul 21, 2026
Related: full search, browse by condition, browse by drug or therapy, browse by sponsor, browse by U.S. city.
Open the official record
The complete protocol, eligibility criteria, and contact information for NCT01569464 live on ClinicalTrials.gov.